Evidence map›Paper›PMID 32371157›Full record

ArticleNeuroscience letters2020

Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy.

Zachary A Sorrentino, Ethan Hass, Niran Vijayaraghavan, Kimberly-Marie Gorion, Cara J Riffe, Jess-Karan S Dhillon, Benoit I Giasson

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Neuroscience letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. NMR unveils an N-terminal interaction interface on acetylated-α-synuclein monomers for recruitment to fibrils.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zachary A SorrentinoDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA; Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.
Ethan HassDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA; Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.
Niran VijayaraghavanDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA; Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.
Kimberly-Marie GorionDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA; Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.
Cara J RiffeDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA; Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.
Jess-Karan S DhillonDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA; Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.
Benoit I GiassonDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA; Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA; McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, 32610, USA. Electronic address: bgiasson@ufl.edu.
University of Florida · US

Funding

Prion and non-prion induction mechanisms of alpha-synuclein pathologyR01NS100876 · NINDS · UNIVERSITY OF FLORIDA · PI BORCHELT, DAVID R, GIASSON, BENOIT I · 2018 to 2022
$1.9M
Mechanisms of Aggregated Alpha-Synuclein Induction and ProgressionR01NS089622 · NINDS · UNIVERSITY OF FLORIDA · PI GIASSON, BENOIT I · 2014 to 2018
$1.6M
Towards Understanding the Initiating Role of Truncated Alpha-Synuclein in NeurodegenerationF30AG063446 · NIA · UNIVERSITY OF FLORIDA · PI SORRENTINO, ZACHARY A · 2019 to 2022
$122k
NIA NIH HHS F30 AG063446NINDS NIH HHS L30 NS089022NINDS NIH HHS R01 NS089622NINDS NIH HHS R01 NS100876
6 · The paper itself

Abstract

Pathologic intracellular inclusions formed from polymers of misfolded α-synuclein (αsyn) protein define a group of neurodegenerative diseases termed synucleinopathies which includes Parkinson's disease (PD). Prion-like recruitment of endogenous cellular αsyn has been demonstrated to occur in animal models of synucleinopathy, whereby misfolded αsyn can induce further pathologic αsyn inclusions to form through a prion-like mechanism. It has been suggested that misfolded αsyn may assume differing conformations which lead to varied clinical and pathological manifestations of disease; this phenomenon bears similarities to that of prion strains whereby the same misfolded protein can produce unique diseases. It is unclear what factors influence the development of unique αsyn strains, however post-translational modifications (PTMs) such as phosphorylation and truncation that are present in misfolded αsyn in disease may play a role due to their modulation of biochemical and structural αsyn properties. Herein, we investigate the prion-like properties of misfolded αsyn polymers containing either phosphomimetic (S129E) αsyn, 5 different major carboxy (C)-truncated forms of αsyn (1-115, 1-119, 1-122, 1-125, and 1-129 αsyn), or a mixture of these PTM containing αsyn forms compared to full-length (FL) αsyn in HEK293T cells and M83 transgenic mice overexpressing A53T αsyn. It is demonstrated that upon peripheral intramuscular injection of these C-truncated or S129E αsyn polymers into M83 mice, prion-like progression and time to disease onset in this mouse model is elongated when any of these PTMs are present, demonstrating that common modifications to the C-terminus of αsyn present in disease modulates the prion-like seeding properties of αsyn.

Indexed as

alpha-SynucleinAnimalsCentral Nervous SystemDisease Models, AnimalHEK293 CellsHumansMiceMice, TransgenicNeuronsParkinson DiseasePhosphorylationPrionsProtein Processing, Post-TranslationalSurvival AnalysisSynucleinopathiesalpha-SynucleinPrionsAmyloidFibrilInclusion formationLewy bodyNeurodegenerationParkinson’s diseasePrionTruncationα-synuclein

Identifiers

PMID32371157
PMCPMC7323740
OpenAlexW3023766147

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.